Skip to content
  • Data Privacy and Policies
  • Careers
  • News & Events
    • Press Releases
    • In the News
    • Articles
    • LinkedIn Feed
    • Meet Us At….
  • Contact
  • Data Privacy and Policies
  • Careers
  • News & Events
    • Press Releases
    • In the News
    • Articles
    • LinkedIn Feed
    • Meet Us At….
  • Contact
Rinri Therapeutics
  • This is Rinri
    • Our Company
    • Our Team
    • Latest News
  • Hearing Loss
    • Hearing Loss
    • The impact
  • Our Approach and Portfolio
    • Overview
    • Our approach to hearing restoration
    • Our hearing restoration product portfolio
    • Conversations
  • Our Clinical Research
    • The First in Human trial of Rincell-1
    • Objective Measures of Neural Health
    • Frequently Asked Questions
  • Patient & Clinicians
    • Patients as partners
    • Working with clinicians
  • This is Rinri
    • Our Company
    • Our Team
    • Latest News
  • Hearing Loss
    • Hearing Loss
    • The impact
  • Our Approach and Portfolio
    • Overview
    • Our approach to hearing restoration
    • Our hearing restoration product portfolio
    • Conversations
  • Our Clinical Research
    • The First in Human trial of Rincell-1
    • Objective Measures of Neural Health
    • Frequently Asked Questions
  • Patient & Clinicians
    • Patients as partners
    • Working with clinicians
  • This is Rinri
    • Our Company
    • Our Team
    • Latest News
  • Hearing Loss
    • Hearing Loss
    • The impact
  • Our Approach and Portfolio
    • Overview
    • Our approach to hearing restoration
    • Our hearing restoration product portfolio
    • Conversations
  • Our Clinical Research
    • The First in Human trial of Rincell-1
    • Objective Measures of Neural Health
    • Frequently Asked Questions
  • Patient & Clinicians
    • Patients as partners
    • Working with clinicians
  • News & Events
    • Press Releases
    • In the News
    • Articles
    • LinkedIn Feed
    • Meet Us At….
  • Data Privacy and Policies
  • Careers
  • Contact
Rinri Therapeutics
  • This is Rinri
    • Our Company
    • Our Team
    • Latest News
  • Hearing Loss
    • Hearing Loss
    • The impact
  • Our Approach and Portfolio
    • Overview
    • Our approach to hearing restoration
    • Our hearing restoration product portfolio
    • Conversations
  • Our Clinical Research
    • The First in Human trial of Rincell-1
    • Objective Measures of Neural Health
    • Frequently Asked Questions
  • Patient & Clinicians
    • Patients as partners
    • Working with clinicians
  • News & Events
    • Press Releases
    • In the News
    • Articles
    • LinkedIn Feed
    • Meet Us At….
  • Data Privacy and Policies
  • Careers
  • Contact
Rinri Therapeutics
  • This is Rinri
    • Our Company
    • Our Team
    • Latest News
  • Hearing Loss
    • Hearing Loss
    • The impact
  • Our Approach and Portfolio
    • Overview
    • Our approach to hearing restoration
    • Our hearing restoration product portfolio
    • Conversations
  • Our Clinical Research
    • The First in Human trial of Rincell-1
    • Objective Measures of Neural Health
    • Frequently Asked Questions
  • Patient & Clinicians
    • Patients as partners
    • Working with clinicians
  • News & Events
    • Press Releases
    • In the News
    • Articles
    • LinkedIn Feed
    • Meet Us At….
  • Data Privacy and Policies
  • Careers
  • Contact

Articlesrinri-therapeutics2026-06-04T12:46:03+00:00

Articles

  • Can a cell therapy for hearing loss be a healthspan blockbuster
rinri-therapeutics2026-06-12T14:02:32+00:00

Can a cell therapy for hearing loss be a healthspan blockbuster?

Articles June 4th, 2026

  • Springer Nature
rinri-therapeutics2026-06-12T14:00:19+00:00

Neural Hearing Loss: Mechanisms, Diagnosis and Treatment Horizons

Springer Nature February 26th, 2026

  • ENT & Audiology News
rinri-therapeutics2026-06-12T13:58:42+00:00

Enhancing care for adults with auditory neuropathy spectrum disorder

ENT & Audiology News November 4th, 2025

  • nature
rinri-therapeutics2026-06-12T13:58:28+00:00

A novel therapeutic pathway to the human cochlear nerve

Nature November 5th, 2024

  • ENT & Audiology News
rinri-therapeutics2026-07-14T05:34:40+00:00

The changing landscape for hearing loss therapeutics

ENT & Audiology September 3rd, 2024

  • Otolog & Neurotology
rinri-therapeutics2026-06-12T13:59:44+00:00

Self-Assessment of Cochlear Health by New Cochlear Implant Recipients

Otology & Neurotology August 1st, 2024

  • Scientific Reports
rinri-therapeutics2026-06-12T13:58:12+00:00

Unlocking the human inner ear for therapeutic intervention – published in Scientific Reports

Scientific Reports December 9th, 2022

  • Wiley
rinri-therapeutics2026-06-12T16:00:18+00:00

Generation of Otic Lineages from Integration-Free Human-Induced Pluripotent Stem Cells Reprogrammed by mRNAs

Wiley March 1st, 2020

  • ScienceDirect
rinri-therapeutics2026-06-12T16:01:32+00:00

The use of animal models to study cell transplantation in neuropathic hearing loss

Science Direct March 14th, 2019

12Next

Get in touch

Thank you for your message. It has been sent.
There was an error trying to send your message. Please try again later.

Rinri Therapeutics Ltd.
Innovation Centre
217 Portobello
Sheffield S1 4DP

Tel. +44 [0] 114 222 4330
Email. enquiries@rinri-therapeutics.com

Legal

Terms and Conditions
Data Privacy and Policies
Cookie Policy

© Rinri Therapeutics Ltd. All Rights Reserved. Registered number 08839972

Page load link
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Go to Top